|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Alzheimer's Disease
'Dementia' is a group of diseases which affect thinking, memory and other brain functions. Alzheimer's is the commonest type of dementia; it mostly affects people over 65. It's due to destruction of brain cells, leading to confusion, loss of memory, behavior and personality changes.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Severe Alzheimer/Dementia Study -DUS44
The purpose of this 24 week, prospective, randomized, parallel-group, double-blind, multi-center study is to compare the effects of two different doses of a Novartis investigational drug in people with severe dementia/Alzheimers. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 4 Participation Duration: The participant will be required to visit the doctor’s office 6 times over about 28 weeks. Protocol Number: CENA713DUS44 Alzheimer's Disease Study - A2203
The purpose of this 90-week, multi-center, randomized, double-blind, placebo-controlled study is to assess the safety, tolerability, and Abeta-specific antibody response of repeated intra-muscular injections with a Novartis investigational drug in patients with mild Alzheimer's Disease.
An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 2 Participation Duration: Participation in this study will require you to go to your doctor's office/clinic about 22 times over about 90 weeks (on average monthly). In addition, you will have to go to the radiologist for an MRI scan 6 times during the study. Protocol Number: CCAD106A2203 |